Idhifa is a drug used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the isocitrate dehydrogenase 2 (IDH2) gene, determined by an FDA-approved IDH2 companion diagnostic test
The global Idhifa market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Idhifa volume and value at global level, regional level and company level. From a global perspective, this report represents overall Idhifa market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Idhifa in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Idhifa manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.
The following manufacturers are covered:
Celgene Corporation
...
Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India
Segment by Type
50mg
100mg
Segment by Application
Hospital
Pharmacy
Summary:
Get latest Market Research Reports on Idhifa. Industry analysis & Market Report on Idhifa is a syndicated market report, published as Global Idhifa Market Professional Survey Report 2019. It is complete Research Study and Industry Analysis of Idhifa market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.